Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

被引：0
|
作者：
Kivitz, Alan [1 ]
Kremer, Joel [2 ]
Legerton, Clarence [3 ]
Palmer, Jacqueline [4 ]
Meng, Xiangyi [4 ]
Pricop, Luminita [4 ]
Singhal, Atul [5 ]
机构：
[1] Altoona Ctr Clin Res, Duncansville, PA USA
[2] Albany Med Coll, Albany, NY 12208 USA
[3] Articularis Healthcare, Low Country Rheumatol, N Charleston, SC USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Southwest Rheumatol, Dallas, TX USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1497
引用
收藏
页数：4
相关论文
共 50 条
  • [21] PATIENT CLUSTERS IDENTIFIED BY MACHINE LEARNING: DATA FROM A POOLED ANALYSIS OF PHASE-3 TRIALS OF SECUKINUMAB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH AXIAL MANIFESTATIONS
    Baraliakos, X.
    Pournara, E.
    Gladman, D. D.
    Mease, P. J.
    Jahandideh, S.
    Coates, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 879 - 879
  • [22] Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: Pooled subgroup analyses by patient age of 4 phase 3 clinical studies
    Warren, Richard
    Guettner, Achim
    Morita, Akimichi
    Gisondi, Paolo
    Cooper, Simon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB186 - AB186
  • [23] The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
    Strand, Vibeke
    Kaeley, Gurjit S.
    Bergman, Martin J.
    Gladman, Dafna D.
    Coates, Laura C.
    Sherif, Bintu
    Hur, Peter
    Parikh, Bhumik
    Gilloteau, Isabelle
    Mease, Philip J.
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E208 - E219
  • [24] SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS BURDEN IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
    Gottlieb, A.
    McInnes, I. B.
    Mease, P.
    Rahman, P.
    Kandala, S.
    Patekar, M.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 349 - 350
  • [25] SECUKINUMAB SAFETY AND TOLERABILITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED SAFETY ANALYSIS OF TWO PHASE 3, RANDOMIZED, CONTROLLED TRIALS (FUTURE 1 AND FUTURE 2)
    Mease, P.
    McInnes, I. B.
    Richards, H.
    Pricop, L.
    Widmer, A.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 870 - 871
  • [26] SECUKINUMAB PROVIDES CLINICAL IMPROVEMENTS IN PATIENTS WITH ACTIVE OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM A POOLED ANALYSIS OF FIVE PHASE 3 STUDIES
    Coates, Laura C.
    Ogdie, Alexis
    Gladman, Dafna D.
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip J.
    RHEUMATOLOGY, 2022, 61
  • [27] Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies
    Ogdie, Alexis
    Gladman, Dafna
    Coates, Laura
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3812 - 3815
  • [28] IMPACT OF HYPERURICEMIA ON CLINICAL PHENOTYPE, COMORBIDITIES, AND RESPONSE TO SECUKINUMAB IN PSORIATIC ARTHRITIS: POST HOC ANALYSIS OF FUTURE AND MAXIMISE STUDIES
    Felten, R.
    Widawski, L.
    Spielmann, L.
    Gaillez, C.
    Bao, W.
    Gottenberg, E.
    Duret, P. M.
    Messer, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 855 - 855
  • [29] Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
    Brunner, Hermine
    Chertok, Elena
    Dehoorne, Joke
    Horneff, Gerd
    Kallinich, Tilmann
    Louw, Ingrid
    Alessio, Maria
    Compeyrot-Lacassagne, Sandrine
    Lauwerys, Bernard
    Martin, Neil
    Marzan, Katherine
    Knibbe, W. Patrick
    Martin, Ruvie
    Zhu, Xuan
    Whelan, Sarah
    Pricop, Luminita
    Lovell, Daniel
    Martini, Alberto
    Ruperto, Nicola
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4382 - 4385
  • [30] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL
    Mease, P. J.
    Kavanaugh, A.
    Reimold, A.
    Tahir, H.
    Rech, J.
    Hall, S.
    Geusens, P.
    Pascale, P.
    Delicha, E. M.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 952 - 953
12345